United States: Wyeth Unable To Vaccinate Itself Against Federal Circuit Remand

Decision: Merck Sharp & Dohme Corp. v. Wyeth LLC, --F.3d__ (Fed. Cir. Nov. 26, 2019) (non-precedential) (DYK, Prost, Wallach)

Holding: The PTAB’s decision declining to find claim 18 of Wyeth’s involved patent obvious was insufficiently supported, and therefore the Court vacated and remanded.

Background: Wyeth’s patent, U.S. 8,562,999, is directed to formulations for stabilizing and inhibiting precipitation of polysaccharide-protein conjugate vaccines. Independent claim 1 reads:

1. A formulation comprising
(i) a pH buffered saline solution, wherein the buffer has a pKa of about 3.5 to about 7.5,
(ii) an aluminum salt and
(iii) one or more polysaccharide-protein conjugates,

wherein the formulation is comprised in a siliconized container means and inhibits aggregation induced by the siliconized container means.

Dependent claim 18 recites: The formulation of claim 1, wherein the one or more polysaccharide-protein conjugate comprises [13 different S. pneumoniae serotype polysaccharides conjugated to a CRM197 polypeptide].

Merck filed two petitions for inter partes review (IPR), IPR2017-00378 and IPR2017-00380. Both petitions challenged claims 1–6, 10, 11, 14, and 17–20. Merck’s obviousness challenge of claim 1 was based on Chiron, Smith, and Elan in the ‘378 IPR, and Chiron and Prevenar in the ‘380 IPR. With respect to claim 18, in each IPR, Merck added Peña to the combinations of references raised against claim 1. Peña disclosed a “13-valent pneumococcal conjugate vaccine with the same serotypes recited by claim 18, but not conjugated to the CRM197 protein.”

PTAB: The Patent Trial and Appeal Board (PTAB) issued two Final Written Decisions holding all the challenged claims, except for claim 18, unpatentable as obvious. As to claim 18, the PTAB stated it was “unable to assess whether the study  [disclosed in Peña] involved a formulation comprising each of the thirteen known serotypes conjugated to a CRM197 polypeptide [the carrier protein], as required by the claim, or if such an attempt was even considered, tried, and successful.” IPR2017-00378, Paper 59, at 44. Merck “ha[d] not provided a reason that a person of skill in the art would have modified Chiron’s formulation to comprise a thirteen valent conjugate,” (Id. at 39) and that “[Merck] ha[d] not provided sufficient evidence for [the Board] to determine whether a skilled artisan who endeavored to modify Chiron’s formulation to yield a 13-valent pneumococcal conjugate vaccine with the same serotypes as in Peña would have had a reasonable expectation of successfully doing so.” Id. at 44. Merck appealed both IPR decisions.

Federal Circuit: The Federal Circuit issued one decision for both IPRs, concluding that the PTAB did not provide a reasoned basis for upholding claim 18 in either Final Written Decision, citing precedent noting that:

“[t]he agency tribunal must make findings of relevant facts, and present its reasoning in sufficient detail that the court may conduct meaningful review of the agency action.” In re Lee, 277 F.3d 1338, 1346 (Fed. Cir. 2002). “The [Board]’s own explanation must suffice for us to see that the agency has done its job and must be capable of being ‘reasonably . . . discerned’ from a relatively concise [Board] discussion.” In re NuVasive, Inc., 842 F.3d 1376, 1383 (Fed. Cir. 2016) (quoting In re Huston, 308 F.3d 1267, 1281 (Fed. Cir. 2002)).

Merck, at *4.

Merck’s expert testified (without contradiction from Wyeth’s expert) that early pneumococcal polysaccharide vaccines included 14-valent and 23-valent unconjugated vaccines which, together, included all 13 serotypes recited in the claim, and that it would have been obvious to combine them into a single vaccine. This evidence was not rebutted.

But would it have been obvious to conjugate the 13 serotypes recited in the claim to the CRM197 protein in a single vaccine? The Federal Circuit found the PTAB’s conclusion that Peña did not show such an attempt “was even considered, tried and successful[,]” insufficient to support a lack of motivation or reasonable expectation of success. Id. at *7. “Obviousness, unlike anticipation, does not require a prior art successful formulation.” Id. There was also evidence that Chiron identified CRM197 as a “particularly preferred” carrier protein and “[Peña] describes the 9-valent version of the vaccine as being conjugated to only the single CRM197 carrier.” Id. There was conflicting testimony about whether the prior art disclosed an 11-valent pneumococcal CRM197 conjugate vaccine. And there was conflicting testimony as to whether a POSITA would “conclude that the 7-valent conjugate vaccine . . . could be expanded to the 13-valent pneumococcal polysaccharide single-carrier CRM197 conjugate vaccine” with a reasonable expectation of success. Id.  at *8. The Federal Circuit found that that PTAB should have addressed the conflicting evidence as to motivation to modify and reasonable expectation of success.

The Federal Circuit also found that the PTAB failed to address the evidence and factual issue of whether a POSITA “would have been dissuaded from using a single carrier protein (i.e. CRM197) due to ‘immune interference.’” Id.  at *9. According to the Federal Circuit:

The fact that Peña did not disclose such a combination fails to answer this central question, and an explanation was particularly necessary given the Board’s finding that the use of CRM197 was obvious with the 7-valent conjugate in claim 17—which also uses CRM197 as a sole carrier protein. We conclude that the Board’s decision is too cryptic to survive judicial review. (emphasis added)

Merck, at *10.

Practical Takeaways

The legal conclusion that a claim would have been obvious depends on at least the four underlying factual issues set forth in Graham v. John Deere Co. of Kansas City, 383 U.S. 1, 17, 86 S.Ct. 684, 15 L.Ed.2d 545 (1966): (1) the scope and content of the prior art; (2) differences between the prior art and the claims at issue; (3) the level of ordinary skill in the pertinent art; and (4) evaluation of any relevant secondary considerations. All four factors must be addressed. Kinetic Concepts, Inc. v. Smith & Nephew, Inc., 688 F.3d 1342,1360 (Fed. Cir. 2012). It generally remains best practice to try to attack rather than rebut a prima facie case of obviousness in light of prosecution history estoppel and litigation implications. 

A patentee, however, might shore up the defenses against a third party petitioning for an IPR with rebuttal evidence such as unexpected results. In such cases, the PTAB sometimes relied on evidence rebutting a prima facie case during prosecution to support denial of the IPR. Coalition for Affordable Drugs V LLC v. Hoffman-LaRoche, Inc., IPR2015-01792, Paper 14 (P.T.A.B. Mar. 11, 2016)  (institution for failure to address objective indicia considered by Examiner during original prosecution); and Merial Ltd. v. Virbac, IPR2014-01279, Paper 13 (P.T.A.B. Jan. 22, 2015) (denying institution for failure to address objective indicia considered by Examiner during original prosecution and noting “Merial was aware of the unexpected results showing which the Examiner found persuasive . . . . Merial should have addressed unexpected results in the first instance.”).

It is well established that the PTAB must support its conclusion with reasoning. In Merck, the Federal Circuit cites several cases on this point. See, e.g., In re Lee, 277 F.3d 1338, 1342  (Fed. Cir. 2002) (“when the issue is obviousness,… ‘[t]he factual inquiry whether to combine references must be thorough and searching.’ … It must be based on objective evidence of record. This precedent has been reinforced in myriad decisions, and cannot be dispensed with.”). See also, In re Stepan Co., 868 F.3d 1342 (Fed. Cir. 2017); In re Grose, 592 F.2d 1161 (CCPA 1979)(an examiner must provide some evidentiary basis for the existence and meaning of the scientific principle relied on in support of an obviousness rejection); and Arendi S.A.R.L. v. Apple Inc., 832 F.3d 1355 (Fed. Cir. 2016).

Therefore, as a patent owner, challenge any unsupported conclusions or reliance on only common sense by either an Examiner or PTAB.

Furthermore, it is improper in determining whether a person of ordinary skill would have been led to a combination of references simply to “[use] that which the inventor taught against its teacher.”  In re Lee, 277 F.3d at 1343, citing W.L. Gore & Assocs. v. Garlock, Inc., 721 F.2d 1540, 1553 (Fed. Cir. 1983). See also, In re Dow Chem. Co., 837 F.2d 469, 473 (Fed. Cir. 1988) ("[t]here must be a reason or suggestion in the art for selecting the procedure used, other than the knowledge learned from the applicant's disclosure” and “[b]oth the suggestion and the expectation of success must be founded in the prior art, not in applicant's disclosure."); Cardiac Pacemakers, Inc. v. St. Jude Medical, Inc., 381 F.3d 1371 (Fed. Cir. 2004). A patentee, therefore, should challenge hindsight reasoning by the PTAB or an Examiner that relies on the patentee’s specification as a roadmap to the claimed subject matter.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions